BRIEF-U.S. FDA, CDC Lift Recommended Pause On Johnson & Johnson COVID-19 Vaccine Use

United States Food and Drug Administration: * FDA AND CDC LIFT RECOMMENDED PAUSE ON JOHNSON & JOHNSON (JANSSEN) COVID-19 VACCINE USE FOLLOWING THOROUGH SAFETY REVIEW

* FDA - AGENCIES UNDERSCORE CONFIDENCE IN JNJ VACCINE’S SAFETY AND EFFECTIVENESS FOLLOWING DATA ASSESSMENT * FDA- FDA, CDC DETERMINED RECOMMENDED PAUSE REGARDING USE OF JOHNSON & JOHNSON VACCINE IN U.S. SHOULD BE LIFTED, USE OF VACCINE SHOULD RESUME.

* FDA - AVAILABLE DATA SUGGEST POTENTIAL BLOOD CLOTS ARE VERY RARE EVENTS * FDA- FDA HAS DETERMINED THAT AVAILABLE DATA SHOW THAT VACCINE’S KNOWN AND POTENTIAL BENEFITS OUTWEIGH RISKS IN INDIVIDUALS 18 YEARS OF AGE AND OLDER. Source text https://www.fda.gov/news-events/press-announcements/fda-and-cdc-lift-recommended-pause-johnson-johnson-janssen-covid-19-vaccine-use-following-thorough Further company coverage: